The oversubscribed round, led by Morningside and Hesperia Capital, will expand SimpliFed's Maternal Health Operating System - a virtual care platform spanning pregnancy, postpartum, gestational diabetes monitoring, mental health screenings and virtual OB services, integrated with EMRs via FHIR/HL7. The raise comes as US maternal mortality sits at 22 deaths per 100k births amid widening OB shortages.
"The Board’s decision to raise funds enables Avacta to continue to retain 100% ownership of our highly promising programs. We believe this decision to overwhelmingly be in the long-term interest of shareholders, such is the potential for our proprietary technology." — Christina Coughlin, CEO, Avacta
🔗 https://www.tamradar.com/funding-rounds/simplifed-series-a-10-8m
Hologic is now private, acquired by Blackstone and TPG in a deal worth up to $79 per share - $76 in cash plus a contingent value right of up to $3 per share tied to breast health revenue targets. Joe Almeida, former CEO of Baxter International and Covidien, takes the helm immediately. Hologic has been delisted from Nasdaq.
“Hologic’s mission is to advance detection and care to improve health outcomes for women worldwide. Investing behind healthcare innovation has been a core thematic focus for TPG over decades, and we have long admired Hologic as an industry leader. We are proud to partner with Hologic and Blackstone to support clinical excellence and deliver meaningful impact for patients.” — Alex Albert, Partner & Co-Head of Healthcare, TPG Capital
🔗 https://www.tpg.com/news-and-insights/blackstone-and-tpg-complete-acquisition-of-hologic
The Canadian startup is building a first-of-its-kind direct-to-consumer fertility insurance platform - subscription-based coverage starting at $20/month spanning diagnostics, IUI and IVF. Unlike employer-tied benefits, Flora's policies travel with the subscriber through job changes. The round was led by ManchesterStory with participation from Slauson & Co., BDC and Adara Venture Partners.
“Fertility is one of the largest uninsured financial risks people face, yet the system today only offers support once you’re already in crisis, and often only if your employer provides it. We’re creating a new category where fertility becomes something you can proactively plan for, not just pay for when it’s too late.” — Laura McDonald, Co-Founder, Flora
Hatteras Venture Partners has joined Incyclix Bio's Series B, backing the ongoing Phase 1/2 trial of INX-315 - a CDK2 inhibitor targeting CDK4/6 inhibitor-resistant ER+/HER2- breast cancer and CCNE1-amplified solid tumours including ovarian cancer. Hatteras partner Kseniya Simpson joins the board.
“We are encouraged by Hatteras’s strong enthusiasm for our CDK2 program and their support in advancing INX-315 toward meaningful clinical outcomes. Additionally, we’re pleased to welcome Kseniya and Christy to our board and look forward to working with them during this pivotal time of growth for Incyclix.” — Patrick Roberts, CEO & Co-Founder, Incyclix Bio
The strategic merger brings together Reprotech's 35+ years of cryostorage infrastructure with TMRW's digital specimen management platform, covering more than one million fertility specimens and partnering with approximately 75% of US fertility centres. The combined entity will operate under the Reprotech banner with TMRW CEO Louis Villalba leading the organisation.
"Cancer vaccines are a new class of treatment seeing promising results in early studies. We are at a pivotal moment for this research. Trials like this and the partnerships that CVC is building, are designed to help bring groundbreaking therapies to patients sooner." — Kristen Dahlgren, Founder & CEO, Cancer Vaccine Coalition "At TMRW, our mission has always been to safeguard life's most precious cells and advance the standard of care. By joining forces with Reprotech, we have the opportunity to bring together trusted infrastructure, national scale, and digital innovation in a way that is truly differentiated in the fertility market. I'm excited to lead this next chapter and help build the future of fertility cryostorage." — Louis Villalba, Chief Executive Officer, TMRW
